title: Efficacy of a single pretransplant donor-specific transfusion and cyclosporin A administered 24 to 48 hours before one-haplotype-mismatched living related donor kidney transplant.
abstract: During the 7-year period from March 1984 to June 1991, 86 haploidentical living related kidney recipients were entered into one of three donor-specific transfusion (DST) and cyclosporine treatment protocols: (1) Multiple pretransplant DSTs with cyclosporine begun after transplant, n = 34; (2) Multiple pretransplant DSTs with cyclosporine begun pretransplant, n = 31; and (3) a single DST 24 to 48 hours before transplant with intravenous cyclosporine initiated after the transfusion, n = 21. Triple immunosuppression (prednisone, azathioprine, and cyclosporine) was continued in all groups after transplant. The 1-year patient (97%, 97%, and 93%, p = not significant) and graft (91%, 90%, and 87%, p = not significant) survival were similar for the three groups. No differences were seen in the incidence of rejection at 1 year (61%, 45%, and 60%, p = not significant) or in the incidence of infectious complications (26%, 42%, and 47%, p = not significant). It is concluded that a single DST given 24 to 48 hours before operation followed by pretransplant cyclosporine is as effective as classic DST conditioning of recipients using either pretransplant or post-transplant cyclosporine. The single DST protocol has the advantage of not eliminating any donors because of sensitization and was less costly and easier to administer.
authors.affiliation: Department of Surgery, University of Cincinnati Medical Center, OH 45267-0558.
authors.forename: C B
authors.initials: CB
authors.lastname: Davies
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: B R
authors.initials: BR
authors.lastname: Cofer
authors.forename: M R
authors.initials: MR
authors.lastname: First
authors.forename: T J
authors.initials: TJ
authors.lastname: Schroeder
mesh_terms: D000328:Adult; D001803:Blood Transfusion; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006085:Graft Survival; D006239:Haplotypes; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000379:methods; D008297:Male; D016853:Muromonab-CD3 / Q000008:administration & dosage; D011300:Preoperative Care; D014019:Tissue Donors
chemical_list: D016853:Muromonab-CD3; D016572:Cyclosporine